BridgeBio to present new data on acoramidis for heart failure at ESC-Heart Failure 2026.

BridgeBio Pharma announced it will present new Phase 3 data on acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), at the ESC-Heart Failure 2026 conference in Barcelona. Bayer, BridgeBio's European partner, will highlight acoramidis' effects on outpatient worsening heart failure. The drug, approved in the US and Europe under different brand names, shows promise in stabilizing transthyretin and improving heart failure outcomes. These presentations could influence treatment approaches for this rare genetic heart condition.